The European Business Association (EBA) has issued a warning that recent amendments to Ukraine’s Tax Code (Bill No. 13420), aimed at supporting defense industry enterprises, could have unintended consequences on the pharmaceutical supply chain. The proposed changes, which seek to regulate the circulation of pharmaceuticals, may jeopardize government medicine procurement programs, leading to potential drug shortages.
In its analysis, the EBA highlights concerns that the regulatory framework introduced by these amendments could interfere with the distribution of essential medicines. The association is urging policymakers to carefully consider the potential economic and public health impacts of these changes. The warnings come at a critical time as Ukraine continues to face challenges in maintaining its healthcare infrastructure amidst ongoing conflict.
The EBA’s report underscores the complex interplay between defense industry support and public health policy. While the government’s focus on bolstering national defense is understandable, the potential disruption to pharmaceutical supply chains raises significant concerns. These amendments may lead to a situation where the procurement of essential medical supplies is compromised, affecting both the civilian population and frontline medical services.